TI
ESPR

Trexquant Investment’s Esperion Therapeutics ESPR Stock Holding History

Trexquant Investment’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,560
Closed -$305K – 1465
2022
Q3 		$305K Buy
+45,560
New +$313K 0.01% 1030
2021
Q2 		– Sell
-15,807
Closed -$443K – 1197
2021
Q1 		$443K Buy
+15,807
New +$466K 0.04% 563
2020
Q3 		– Sell
-16,092
Closed -$826K – 1282
2020
Q2 		$826K Buy
+16,092
New +$673K 0.06% 462
2019
Q3 		– Sell
-20,569
Closed -$957K – 927
2019
Q2 		$957K Buy
20,569
+6,166
+43% +$290K 0.09% 331
2019
Q1 		$578K Buy
14,403
+6,722
+88% +$302K 0.04% 549
2018
Q4 		$353K Sell
7,681
-11,438
-60% -$551K 0.02% 733
2018
Q3 		$848K Buy
+19,119
New +$878K 0.06% 395
2017
Q4 		– Sell
-16,591
Closed -$832K – 1095
2017
Q3 		$832K Buy
+16,591
New +$800K 0.21% 120
2016
Q4 		– Sell
-22,272
Closed -$308K – 1008
2016
Q3 		$308K Buy
+22,272
New +$252K 0.07% 469
2016
Q1 		– Sell
-50,800
Closed -$1.13M – 983
2015
Q4 		$1.13M Sell
50,800
-100
-0.2% -$2.52K 0.1% 342
2015
Q3 		$1.2M Buy
+50,900
New +$3.19M 0.1% 345

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Trexquant Investment's ESPR Position: Q4 2022 in Review

Trexquant Investment sold out of Esperion Therapeutics (ESPR) in Q4 2022, closing a stake of 45,560 shares — an estimated $305K sold.

Trexquant Investment first reported a position in ESPR in Q3 2015 and held it in 11 quarters. The position peaked at $1.2M in Q3 2015. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

  • Trexquant Investment reported no remaining Esperion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Trexquant Investment sold 45,560 Esperion Therapeutics shares in Q4 2022, an estimated $305K.
  • Trexquant Investment first reported a position in Esperion Therapeutics in Q3 2015 and held it in 11 quarters.
  • Trexquant Investment's Esperion Therapeutics position peaked at $1.2M in Q3 2015.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Trexquant Investment's 13F filing for Q4 2022, filed 13 Feb 2023.